Hikma PharmaceuticalsMEX:HIKN 80 OCF Margin % is 16.26% as of Dec. 2025, which is 22% below its 10-year median of 20.96. GuruFocus rates MEX:HIKN with a GF Score™ of 80/100 and a GF Value™ of MXN424.07. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 60.06% on this metric.
The historical rank and industry rank for Hikma Pharmaceuticals's OCF Margin % or its related term are showing as below:
MEX:HIKN'
s OCF Margin % Range Over the Past 10 Years
Min: 13.02 Med: 20.96 Max: 24.99
Current: 12.93
During the past 13 years, the highest OCF Margin % of Hikma Pharmaceuticals was 24.99%. The lowest was 13.02%. And the median was 20.96%.
MEX:HIKN's OCF Margin % is ranked better than 60.06% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs MEX:HIKN: 12.93
Hikma Pharmaceuticals OCF Margin % Related Terms
Hikma Pharmaceuticals OCF Margin % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HIKN vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (MEX:HIKN) has a OCF Margin % of 16.26% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hikma Pharmaceuticals and its competitors. This is 22% below median its historical median of 20.96. Over the past decade, Hikma Pharmaceuticals' OCF Margin % has ranged from 13.02 to 24.99. According to the industry distribution chart, Hikma Pharmaceuticals ranks #383 out of 959 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Hikma Pharmaceuticals' OCF Margin % too high?
Hikma Pharmaceuticals' current OCF Margin % of 16.26% is 22% below median its 10-year median of 20.96. Over the past 10 years, this metric has ranged from a low of 13.02 to a high of 24.99. The Drug Manufacturers industry median OCF Margin % is 9.95. Hikma Pharmaceuticals' value of 16.26% is 63.4% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #383 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #383 out of 959 companies for OCF Margin %. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median OCF Margin % is 9.95. Hikma Pharmaceuticals' value of 16.26% is 63.4% above this benchmark. Historically, Hikma Pharmaceuticals' own OCF Margin % has ranged from 13.02 to 24.99 over the past decade. While the company's 10-year median is 20.96 vs. the industry median of 9.95, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current OCF Margin % of 16.26% is 63.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current OCF Margin % is 16.26%, which is 22% below median its own 10-year median of 20.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Hikma Pharmaceuticals (MEX:HIKN) has a current OCF Margin % of 16.26%. The stock's GF Value™ is MXN424.07, compared to a current price of MXN307.48 — trading 27.5% below its estimated fair value. The current OCF Margin % is 16.26%, which is 22% below median its 10-year median of 20.96 and 63.4% above the Drug Manufacturers industry median of 9.95. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Hikma Pharmaceuticals (MEX:HIKN), the current OCF Margin % is 16.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (MEX:HIKN) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN307.48 is trading 27.5% below its estimated GF Value™ of MXN424.07.
Key valuation signals for MEX:HIKN:
OCF Margin %: 16.26% (22% below median its 10-year median of 20.96)
GF Value™: MXN424.07 vs. price of MXN307.48 (27.5% below fair value)
Industry Position: 63.4% above the Drug Manufacturers median (#383 of 959)
No single metric tells the full story. See the MEX:HIKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score
Get the complete analysis for MEX:HIKN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HIKN has been successfully added to your 
